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In a recent issue of Alzheimer’s Research & Th  erapy, we 
read with great interest the discussion by Szigeti and 
Doody [1] of including early-onset Alzheimer’s disease 
(EOAD) (under age 65) in clinical trials. Successful 
enroll  ment is a challenge in most Alzheimer’s disease 
(AD) trials, and permitting the participation of these 
young motivated patients could aid recruitment. EOAD 
can be categorized as AD caused by autosomal dominant 
mutations (ADAD) in the amyloid precursor protein 
(APP), presenilin-1 (PSEN1), or presenilin-2 (PSEN2) 
genes and as AD in individuals not known or suspected 
to harbor such mutations, which we here refer to as 
sporadic AD (SAD).
We agree with the authors that SAD cases under age 65 
should be included in AD trials. Th   e literature describing 
these cases does not suggest that clinical or biological 
diﬀ  erences warrant exclusion. We take pause, however, 
with the recommendation of categorical enrollment of 
ADAD patients in trials. Inclusion of persons with ADAD 
should be dependent upon the nature of the causative 
mutation, the drug under investigation, and the study 
objectives. More than 200 AD-causing mutations are 
known, and predicting the impact of all disease-causing 
mutations on drug eﬃ   cacy is diﬃ   cult. APP muta  tions are 
most frequent in the β- and γ-secretase cleavage regions 
and result in increases in the levels of both Aβ42 and Aβ40, 
Aβ42 alone, or the ratio of Aβ42 to Aβ40 [2,3]. Aβ40 resultant 
from processing of mutated APP is resis  tant to degra-
dation by neprilysin [4,5]. γ-Secretase inhibitors may lack 
eﬃ   cacy in preventing APP cleavage by enzymes resultant 
from mutated PSEN genes [6,7]. On pathological exami-
nation, the brains of persons with ADAD can demon-
strate atypical morphology, distribu  tion, and composition 
of Aβ deposits [2]. Biological diﬀ  er  ences between ADAD 
and SAD might manifest similar diﬀ  erences in response 
or side-eﬀ  ect proﬁ   le to a given intervention and thus 
should be considered care  fully before patients with 
ADAD are enrolled in trials.
In phase I studies, biological diﬀ  erences  between 
ADAD and SAD could translate to diﬀ  erent dose require-
ments since younger patients with ADAD are likely to 
have a more rapid drug metabolism. Females may also be 
premenopausal, making teratogenicity a consideration. In 
phase II, diﬀ   erences in ADAD could have eﬀ  ects  on 
outcomes and interpretation since ADAD participants 
might be overrepresented, given that the percentage of 
SAD patients who qualify for trials is low, ADAD patients 
have fewer barriers to participation, and trials are often 
conducted at academic centers where ADAD is studied. 
Alternatively, persons with ADAD might theoretically be 
enrolled in larger late-stage trials with a predeﬁ  ned plan 
to analyze eﬃ   cacy and safety of this AD subtype separ-
ately. Acceptance of this approach by regulatory bodies 
and willingness of sponsors to risk an impact on the 
overall trial signiﬁ  cance, however, are uncertain.
Th  e Dominantly Inherited Alzheimer’s Network and 
the Alzheimer’s Prevention Initiative are preparing to 
conduct prevention clinical trials in ADAD, in part 
addressing the important need for clinical drug research 
in this population. Th   ese studies may not enroll persons 
already demented with ADAD. In accordance with the 
principle of beneﬁ  cence, AD trial design should permit 
exami  nation of eﬃ   cacy in all possible disease-suﬀ  ering 
popula  tions. For every study, however, substantial 
consideration must be given to the issues of whether to 
include speciﬁ  c persons with ADAD and of how the data 
will be analyzed when the study is complete.
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